Similar documents
CHEMOTHERAPY MAY. 1988

Fig. 1 Chemical structure of DL-8280

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.


Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St


CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

VOL.42 S-1


CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

CHEMOTHERAPY

Fig. 1 Chemical structure of norfioxacin (AM-715)

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates


CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin


VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega


Table1MIC of BAY o 9867 against standard strains

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)

Fig.1 Chemical structure of BAY o 9867

Title 神経因性膀胱にともなう排尿障害に対する塩酸ブナゾシンの臨床効果 - 二重盲検比較試験による検討 - 小柳, 知彦 ; 富樫, 正樹 ; 丸, 彰夫 ; 折笠, 精一 ; 相馬, Author(s) 崎, 淳 ; 安田, 耕作 ; 阿曽, 佳郎 ; 本問, 之夫 ; 三宅, 弘厚生 ; 熊

988 CHEMOTHERAPY NOV. 1971

VOL. 34 S-2 CHEMOTH8RAPY 913


Fig. 1 Chemical structure of KW-1070

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )


CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.



Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad

VOL. 43 NO. 4


CHEMOTHERAPY


1272 CHEMOTHERAPY MAR. 1975


CHEMOTHERAPY

CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation

Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic


VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains


THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus


Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

日本職業・災害医学会会誌第54巻第6号

Key words: Norfloxacin (NFLX), Infectious enteritis, Double-blind method



Table 1 Profiles of 28 patients with Legionella pneumonia in Japan, a) Y Taguchi, personal communication b) M. Hayase, personal communicatio

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1


VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum

VOL.27 CHEMOT S-1 HERAPY 185 に感 性 を示 して い たが,臨 床 的 に は無 効 で あ った 本 症 る 細 菌学 的 に も検 討 した が,起 炎菌 と考 え られ る細 菌 を 例 で は 基礎 疾 患 と して縦 隔 洞腫 瘍 が あ り,既 に 副 腎

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -

Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination


Therapy for Asthenopia in Cases of Convergence Insufficiency Hiroko TAKASAKI, C.O.J., Nobuko INAGAMI, C.O.J., and Kayoko TAKENAWA, C.O.J.. Orthoptic c


Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date URL


CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac


VOL.39 S-3

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

CHEMOTHERAPY JUNE 1986

CHEMOTHERAPY JAN Fig. 1 Structure of cephradine


semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG

400 CHEMOTHERAPY JAN Table 1 Cases of drop outs



Key words: Antibodies to Leptospira, Tokyo, Uveitis

Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo

Physical and Psychological Effects of Stressors in Female College Students Reizou Mita*1, Konosuke Tomabechi*1, Isao Yamaguchi*1, Naoko Soeno*1, Shuhe

Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection


<95DB8C9288E397C389C88A E696E6462>

明海大学歯学雑誌　３７‐２／１．秦泉寺

VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin

) 5 Lawton QOL 4 4 QOL Lawton 4) Philadelphia Geriatric Center Affect Rating ScaleARS ARS QOL 5) HDS R

Visual Evaluation of Polka-dot Patterns Yoojin LEE and Nobuko NARUSE * Granduate School of Bunka Women's University, and * Faculty of Fashion Science,

Transcription:

Fig. 1 Chemical structure of norfloxacin Table 1. Institutes attended to the study The Department of Dermatology, Defense Medical College The Department of Dermatology, School of Medicine, Teikyo University The Department of Dermatology, Kanto Teishin Hospital The Department of Dermatology, Faculty of Medicine, University of Tokyo The Department of Dermatology, Central Hospital of Japan National Railway The Department of Dermatology, Japanese Red Cross Medical Center The Department of Dermatology, School of Medieine, Toho University The Department of Dermatology, Kanto Chuo Hospital The Department of Dermatology, The 2nd Hospital, Nippon Medical School The Department of Dermatology, Kanto Rosai Hospital Table 2 Diagnosis Group 1 Folliculitis, Pustular acne Group 2 Furuncle, Furunculosis, Carbuncle Group 3 Impetigo contagiosa, Eczema impetiginosum Group 4 Phlegmon, Erysipelas, Superficial Group 5 lymphangitis, Lymphadenitis Abscess, Cystic acne (Acne conglobata) Suppurative Infected atheroma hidradenitis, Group 6 Ulcer due to burn, Postoperative ulcer, Traumatic ulcer, Miscellaneous ulcer secondary to skin diseases, Decubitus

Table 9 Background characteristics Table 10 Subjective and objective symptom

Fig. 2 Appearance of symptom before treatment in each group Group 1 n=28 Group 4 n=15 Group 5 n=30 Group 3 n=10 Group 6 n=6

Fig. 3 Efficacy on symptom in each group Group 1 Group 4 Group 2 Group 5 Group 3 Group 6

Table 11 Global improvement rating for each group classified by the type of disease

Table 12 Global improvement rating classified by the severity in each group

Fig. 4 Appearance and global improvement rating for isolated organisms Table 13 Causative organism in each group classified by the type of disease

Table 14 Bacteriological response for each group classified by the type of disease Fig. 5 Sensitivity distribution of clinical isolates Fig. 6 Sensitivity distribution of clinical isolates

Fig. 7 Sensitivity distribution of clinical isolates Table 15 Results of laboratory findings

Table 16 Global utility rating for each group classified by the type of disease

CLINICAL EXPERIENCE OF NORFLOXACIN(AM-715) IN SUPERFICIAL PYOGENIC INFECTIONS KEIICHI FUJITA The Department of Dermatology, Defence Medical College HISASHI TAKAHASHI, OSAMU KANEKO, TOMOKO SHIMIZU, KENICHIRO CHIKAKANE and TOSHIHIKO ABE The Department of Dermatology, School of Medicine, Teikyo University EIICHIRO NONAMI, NAOSHIGE HORSE, KEIKO SHISHIBA and MICHIRO SHIMOTSUMA The Department of Dermatology, Kanto Teishin Hospital ATSUSHI KUKITA, SHINICHI WATANABE, KIYOSHI YAMADA The Department of Dermatology, YASUO KUBOTA and TOORU SOMEYA Faculty of Medicine, University of Tokyo YASUSHI WATANABE, KOUJI YAMADA, TAKASHI NAGASHIMA MIHOKO YOKOYAMA and EIKO MANO The Department of Dermatology, Central Hospital of Japan National Railway TAKASHI ANZAI, KUMIKO JITSUKAWA, TETSUZAN KANEMARU and YOUKO NIIMURA The Department of Dermatology, Japanese Red Cross Medical Center SUSUMU ONODA The Department of Dermatology, School of Medicine, Toho University MUNEKAZU NISHIWAKI, TAKUYA KITAJIMA and HARUKO HINO The Department of Dermatology, Kanto Chuo Hospital MITSUYOSHI HONDA and SATOMI HATTORI The Department of Dermatology, The 2nd Hospital, Nippon Medical University TAKANORI TOMIZAWA, JUNK() YAMAGUCHI and YOSHIO TAKEUCHI The Department of Dermatology, Kanto Rosai Hospital A new synthetic antibacterial agent, norfloxacin (AM-715) was studied clinically on patients with superficial pyogenic infections at daily dose of 600 mg orally in the field of dermatology, and the following results were obtained. 1. Out of 141 cases, clinical efficacy was evaluated in 124 cases. The overall clinical efficacy was excellent (cured or remarkably improved) in 66.9%, excellent or moderately improved in 86.3%. Within evaluation for each group classified by the type of diseases, clinical efficacies on patient with furuncle, furunculosis and carbuncle (group 2), on patients with impetigo contagiosa, eczema impetiginosum (group 3) on patients with phlegmon, erysipelas, superficial lymphangitis (group 4) and on patients with abscess, suppurative hidradenitis (group 5) were 91.4%, 90%, 100%, and 90%, respectively. Higher clinical responses were obtained in these four groups than the responses in the other patients with folliculitis (group 1) and ulcer (group 6). 2. Overall clinical efficacies classified by species of causative organisms were 95% in patients with S. aureus 84.2% in patients with S. e pidermidis, 87.5% in patients with GNR except for P. aerugtnosa and 75% in patients with P. aeruginosa. 3. MICs distribution of norfloxacin against all strains of clinical isolates S. aureus and S.epidermi-

dis were superior to those of CEX at one or more tubes. 4. Side effect was observed in one case who complained of skin eruption. In the clinical laboratory findings, elevations of GOT, GPT and Al-P were observed in a few cases, but those were normalized after termination of administration. It is considered from above results that norfloxacin (AM-715) is an useful antibacterial agent for the treatment of superficial pyogenic infections in the field of dermatology.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック